Department of Error
- PMID: 33610212
- DOI: 10.1016/S0140-6736(21)00387-1
Department of Error
Erratum for
-
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.Lancet. 2021 Feb 6;397(10273):487-498. doi: 10.1016/S0140-6736(21)00125-2. Lancet. 2021. PMID: 33549193 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
